SCHEMBL2170049

SCHEMBL2170049

Cc1ccc(F)cc1C(=O)N1N(C2C3CC4CC(C3)CC2C4)C(=O)C1(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.40
HCRTR2 O43614 3/20 0.40
PDE2A O00408 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
KCNK3 O14649 2/20 0.32
KCNK9 Q9NPC2 2/20 0.32
CNR2 P34972 2/20 0.32
HSD11B1 P28845 1/20 0.31
HSD17B10 Q99714 1/20 0.30
CYP2C19 P33261 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30
EPHX2 P34913 2/20 0.30
HTR7 P34969 1/20 0.30
CNR1 P21554 1/20 0.30
USP2 O75604 1/20 0.30
P2RX7 Q99572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3239807 0.91 MEN1 (0.32) HCRTR1HCRTR2PDE2AMEN1POLB
SCHEMBL2170598 0.90 CES2 (0.36) MEN1KMT2ACNR2EPHX2
SCHEMBL2169055 0.89 HSD17B10 (0.39) HCRTR1HCRTR2MEN1POLBKMT2A
SCHEMBL2169787 0.88 HCRTR1 (0.38) HCRTR1HCRTR2MEN1KMT2ACNR2
SCHEMBL2169955 0.88 CPS1 (0.36) KMT2AEPHX2
SCHEMBL13368764 0.87 HCRTR1 (0.40) HCRTR1HCRTR2CNR2HSD11B1P2RX7
SCHEMBL2169753 0.86 P2RX7 (0.42) MEN1POLBKMT2AHSD11B1P2RX7
SCHEMBL2170340 0.84 HCRTR1 (0.42) HCRTR1HCRTR2KMT2AP2RX7
SCHEMBL2169693 0.84 ITGB1 (0.42) MEN1POLBKMT2ACYP2C19USP2
SCHEMBL2170275 0.82 ALDH1A1 (0.40) MEN1POLBKMT2AHSD11B1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US claimed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP claimed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US claimed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
EP-2348019-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME Kowa Company, Ltd. (JP) 2011-07-27 EP disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
WO-2010050191-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME 興和株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 HCRTR1 1687/4885HCRTR2 1345/4885PDE2A 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.